22 / 38
N = 56 (%)
PFS (median, mo)
2.9
OS (median, mo)
5.3
Response rate, n (%)
Partial response
3 (5)
Stable disease
23 (41)
Progressive disease
23 (41)
Not evaluabe
7 (13)
CA19-9 response (maximal response/baseline), n (%)
>1
19 (34)
0.5–1
15 (27)
<0.5
10 (18)
Not evaluable
10 (18)
Not measurable
2 (4)
Advanced disease, OS (median, mo)
All
24.2
FOLF(IRIN)OX ↔ gemcitabine+(nab-paclitaxel)
à
nal-IRI+5-FU/LV
25.5
Gemcitabine+nab-paclitaxel
à
nal-IRI+5-FU/LV
23.0
Gemcitabine+nab-paclitaxel
à
Gemcitabine/capecitabine
à
nal-IRI+5-FU/LV
28.6
Other
23.0
MSKCC. Single centre experience: Efficacy and response
Glassman DC, et al. J Clin Oncol 2018;
36 (suppl 4S): 471 (and poster)